| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.2M | -50.9% | +710.4% |
| Cost of Revenue | $10K | -69.7% | -85.9% |
| R&D Expense | $18.8M | +19.1% | -27.2% |
| SG&A Expense | $7.6M | -18.7% | -80.8% |
| Operating Income | -$12.2M | -426.2% | +80.9% |
| Net Income | -$12.8M | -492.7% | +80.3% |
| EPS (Basic) | -$0.04 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $49.7M | +132.4% | +43.7% |
| Short-term Investments | $66.3M | -43.6% | -70.4% |
| Accounts Receivable | $2.3M | +6.9% | -19.4% |
| Inventory | $158K | -6.0% | -75.2% |
| Current Assets | $122.5M | -15.5% | -54.4% |
| Total Assets |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$50.6M | — | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | $108.2M | — | — |
| Financing Cash Flow | -$45.6M | — | — |
| Free Cash Flow | -$50.6M | — | — |
| -500.0% |
| +77.8% |
| EPS (Diluted) | -$0.04 | -500.0% | +77.8% |
| $205.9M |
| -8.7% |
| -35.9% |
| Current Liabilities | $21.7M | -37.7% | -39.7% |
| Long-term Debt | $56.5M | +0.7% | -43.4% |
| Total Liabilities | $85.8M | -10.8% | -39.9% |
| Stockholders' Equity | $120.2M | -7.2% | -32.7% |